<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00545337</url>
  </required_header>
  <id_info>
    <org_study_id>HMR1964A_3505UA</org_study_id>
    <nct_id>NCT00545337</nct_id>
  </id_info>
  <brief_title>Glulisine + Lantus in Type I Patients</brief_title>
  <official_title>26-week, International Multicenter, Open, Non-randomized Phase III Clinical Trial for Evaluation of Efficacy and Safety of Insulin Glulisine (HMR1964) Injected Subcutaneously in Subjects With Type 1 Diabetes Mellitus Also Using Insulin Glargine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy (in terms of change HbA1c from baseline to endpoint) and safety (in
      terms of adverse events, clinical chemistry, lipids, hematology) of insulin glulisine (HMR
      1964) in subjects with type I diabetes mellitus
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of HbA1c</measure>
    <time_frame>from baseline to endpoint</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of HbA1c</measure>
    <time_frame>from baseline to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose parameters, hypoglycemic episodes and dosage of the mealtime and basal insulins</measure>
    <time_frame>from baseline to endpoint</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insuline glulisine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type I diabetes mellitus (onset of diabetes under the age of 40),

          -  an HbA1c range of &gt;6.5 - &lt;11%,

          -  and on multiple injection regimen (more than 1 year of continuous insulin treatment),

          -  body mass index &lt;35.

        Exclusion Criteria:

          -  Active proliferative diabetic retinopathy,

          -  Diabetes other than type I diabetes mellitus,

          -  Pancreatectomised subjects,

          -  Subjects who have undergone pancreas and or islet cell transplants,

          -  Requiring treatment with not permited drugs during the study,

          -  Previous treatment (in the period not less than 1 month before the beginning of the
             trial) with insulin glargine,

          -  Hypersensitivity to insulin,

          -  Major systemic diseases,

          -  Impaired hepatic or renal function

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volodymyr Moshchych</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2007</study_first_submitted>
  <study_first_submitted_qc>October 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2007</study_first_posted>
  <last_update_submitted>October 15, 2009</last_update_submitted>
  <last_update_submitted_qc>October 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

